Comparison of the vasoconstrictor effects of the selective 5-HT(1D)-receptor agonist L-775,606 with the mixed 5-HT(1B/1D)-receptor agonist sumatriptan and 5-HT in human isolated coronary artery

British Journal of Clinical Pharmacology

Volumn 49, Issue 2, 2000, Pages 126-131

  Longmore, Jenny ^a,b   Maguire, J J ^a,b   MacLeod, A ^a,b   Street, L ^a,b   Schofield, W N ^a,b   Hill, R G ^a,b  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

5 HT receptor agonists; Human coronary arteries; Vasoconstriction

Indexed keywords

1 [2 (3 FLUOROPHENYL)ETHYL] 4 [3 [5 (1,2,4 TRIAZOL 4 YL) 1H INDOL 3 YL]PROPYL]PIPERAZINE; SEROTONIN; SEROTONIN 1D AGONIST; SEROTONIN AGONIST; SUMATRIPTAN; UNCLASSIFIED DRUG;

ADULT; ARTERY CONSTRICTION; ARTICLE; CLINICAL ARTICLE; CORONARY ARTERY; CORONARY ARTERY CONSTRICTION; FEMALE; HUMAN; HUMAN TISSUE; ISOLATED ARTERY; MALE; PRIORITY JOURNAL;

ADULT; ANALYSIS OF VARIANCE; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; PIPERAZINES; POTASSIUM CHLORIDE; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN AGONISTS; SUMATRIPTAN; VASOCONSTRICTION;

EID: 0033969426     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2000.00129.x     Document Type: Article

References (23)

1. 1 Willett F, Curzen N, Adams J, Armitage M. Coronary vasospasm induced by subcutaneous sumatriptan. Br Med J 1992; 304: 1415.
2. 2 Lloyd DK, Simmons V. Adverse reactions associated with sumatriptan. Lancet 1993; 341: 1092.
3. 3 O'Connor P, Gladstone P. Oral sumatriptan-associated myocardial infarction. Neurol 1995; 45: 2274-2276.
4. 4 Ottervanger JP, Paalman JJA, Boxma GL, Stricker BHC. Transmural myocardial infarction with sumatriptan. Lancet 1993; 341: 861-862.
5. 5 Houghton LA, Foster JM, Whorwell PJ, Morris J, Fowler P. Is chest pain after sumatriptan oesophageal in origin. Lancet 1994; 344: 985-986.
6. 6 MacIntyre PD, Bhargava B, Hogg KJ, Gemmill JD, Hillis WS. Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation 1993; 87: 401-405.
7. 7 Humphrey PPA, Feniuk W. Mode of action of the antimigraine drug sumatriptan. Trends Pharmacol Sci 1991; 12: 444-446.
8. 1Dβ receptor subtype in human and bovine cerebral arteries. Mol Pharmacol 1993; 44: 242-246.
9. 9 Ullmer C, Schmuck K, Kalkman HO, Lubbert H. Expression of serotonin receptor mRNAs in blood vessels. FEBS Lett, 1995; 370: 215-221.
10. 1B-receptors. Br J Clin Pharmacol 1998; 46: 577-582.
11. 1D-immunoreactivity within the human trigemino-cerebrovascular system: implications for the discovery of new anti-migraine drugs. Cephalalgia 1997; 17: 833-842.
12. 12 Cumberbatch MJ, Hill RG, Hargreaves RJ. Rizatriptan has central antinociceptive effects against durally evoked responses, Eur J Pharmacol 1997; 328: 37-40.
13. 13 Williamson DJ, Shepheard SL, Hill RG, Hargreaves RJ. The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation. Eur J Pharmacol 1997; 328: 61-64.
14. 1D receptor agonists as potential antimigraine agents. J Med Chem 1997; 40: 3501-3503.
15. 1D-receptor agonists and human coronary artery reactivity in vitro: crossover comparisons of 5-HT and sumatriptan with MK-462 and L-741,519. Br J Clin Pharmacol 1996; 42: 431-441.
16. 2 receptor activation. Eur J Pharmacol 1989; 161: 91-94.
17. 2 receptors in serotonin-induced contraction of human isolated coronary arteries. Circulation 1994; 90: 1141-1153.
18. 18 Nilsson T, Longmore J, Shaw D, et al. Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur J Pharmacol 1999; 372: 49-56.
19. 19 Maassen VanDenBrink A, Reekers M, Bax WA, et al. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998; 98: 25-30.
20. 20 Golino P, Piscioni F, Willerson JT, et al. Divergent effects of serotonin on coronary artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N Engl J Med 1991; 324: 641-648.
21. 21 McFadden EP, Clarke JG, Davies GJ, et al. Effect of intracoronary serotonin on coronary vessels in patients with stable angina and patients with variant angina. N Engl J Med 1991; 324: 648-654.
22. 1D agonist. Br J Clin Pharmacol 1997; 43: 49-54.
23. 23 Beer MS, Middlemiss DN, Stanton JA, et al. An in vitro pharmacological profile of rizatriptan. Headache 1997; 37: 223.